Implantica completes first RefluxStop procedures in the United States
Medtech firm Implantica has performed its inaugural RefluxStop procedures in the U.S., marking the entry of its acid reflux treatment device into the American market.
Liechtenstein-based medical technology company Implantica AG has successfully completed the first surgeries using its RefluxStop device in the United States. The device is designed to treat gastroesophageal reflux disease by addressing the mechanical causes of acid reflux rather than relying solely on pharmaceutical intervention.
Entering the U.S. market represents a significant operational milestone for Implantica, as it provides access to the largest medical device market in the world. The company aims to position the implant as a clinical alternative to traditional procedures, such as Nissen fundoplication, or long-term acid-suppressing medication.
With this rollout, Implantica enters a competitive space involving established gastrointestinal surgical equipment manufacturers. The company is now expected to track procedural outcomes and patient recovery data to assess the device’s performance within the U.S. healthcare infrastructure.